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ABSTRACT
Objective: To investigate the role of the HS1,2 enhancer
polymorphisms as a new candidate marker for rheumatoid
arthritis (RA) and to define the possible association with
autoantibody positivity and clinical outcome.
Methods: Genomic DNA was obtained from two cohorts
of patients with RA (100 with early RA (ERA) and 114
with longstanding RA (LSRA)) and from 248 gender-
matched controls from the same geographical area.
Clinical and immunological characteristics were recorded
for all the patients.
Results: The percentage of the 2/2 genotype was higher
in patients with ERA (27.0%), and in patients with LSRA
(34.2%), than in controls (14.9%) (ERA: OR=2.11 (95%
CI 1.20 to 3.70) vs controls; LSRA: OR=2.96 (95% CI
1.76 to 5.00) vs controls). A lower representation of allele
*3 was present in patients with ERA (2.0%) than in
controls (6.0%; OR=0.32 (95% CI 0.11 to 0.91)). No
significant associations were found between polymorph-
isms and autoantibodies positivity.
Conclusion: The HS1,2A allele *2 associates with early
and longstanding RA.
Studies of twins clearly show a genetic contribu-
tion to disease susceptibility in rheumatoid arthri-
tis (RA).
1 The most important genetic risk factor is
in the polymorphic HLA region. The HLA-DRB1
alleles, encoding for shared epitope, confer a higher
risk for development of RA.
2 The association exists
for RA that is characterised by the presence of anti-
cyclic citrullinated peptide (anti-CCP) antibodies.
3
Other genetic associations have been found in
recent years (eg, PTPN22).
4
Recently, a polymorphism of the enhancer
HS1,2A of the Ig heavy 39 regulatory region (IgH
39RR-1) at the 39 of the constant alpha (C-alpha)
genes has been associated with IgA nephritis,
coeliac disease, systemic sclerosis and psoriasis.
5–8
In these diseases, the variation of allelic frequencies
involves allele *2, which has one consensus site for
the NF-kB transcription factor missing in the
second more frequent allele *1.
9 The IgH 39
regulatory region is active in the transcription of
the heavy constant genes for class switch recombi-
nation and in the Ig transcription.
10
The major aim of this study was to investigate a





A cohort of 100 patients with early RA (ERA,
disease duration ,12 months), at the Division of
Rheumatology of the Catholic University (Rome,
Italy) was studied. Patients fulfilled the American
College of Rheumatology criteria for RA.
11 The
disease status for each patient was assessed.
Detailed assessment at study entry (baseline), at
6 months and at 1 year included the disease
activity score (DAS), complete tender and swollen
joint count, acute-phase reactants (erythrocyte
sedimentation rate (ESR) and C-reactive protein
(CRP)), as well as visual analogue scale (0–
100 mm) for global disease activity. All patients’
serum samples were tested for anti-CCP, IgM
rheumatoid factor (RF) and IgA RF autoantibodies,
following ELISA standard techniques. Treatment
was based on methotrexate (MTX) for 3 months
(up to 20–25 mg/week) and etanercept after
3 months if the DAS was not sufficiently lowered
with MTX only, to reach clinical remission (DAS44
,1.6).
A second, completely independent cohort of 114
patients with RA with a long disease duration
(more than 1-year’s disease duration, longstanding
RA (LSRA)) was included in the study and the
same measures for disease activity were collected.
All these patients with LSRA were receiving MTX
in combination with the tumour necrosis factor a
blocker because of severe, progressive disease.
Collection of DNA samples
Genomic DNA was isolated from peripheral
venous blood of patients and controls with a
FlexiGene DNA kit (Quiagen, Valencia, California,
USA), according to the instruction given by
manufacturer. The control sample comprised 248
unrelated, healthy controls of both sexes. Each
control was asked to supply name, birthplace,
language and ethnicity for three generations in
order to exclude recent admixture. The patients
and control subjects were white subjects of Italian
origin, from the same geographical area and gave
their informed consent to participate in the study.
HS1,2A genotyping
Alleles of the HS1,2A enhancer were determined
through two PCRs. The first was on genomic
DNA, selective for the IgH 39RR at the 39 of
C-alpha 1 gene and amplified a fragment of
5404 bp, the second was a nested PCR to amplify
the polymorphic HS1,2A fragment varying from
465 to 287 bp (fig 1). The first PCR was performed
with primers SA2.5 forward 59-GGATCCCTG
TTCCTGATCACTG-39 and A2R reverse
59-GCCCTTCCTGCCAACCTG-39; PCRs were
carried out in 50 ml reaction volume containing
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was performed using the primers P3 forward 59-GACTCATT-
CTGGGCAGACTTG-39 and D3 reverse 59-GTCCTGGTCC-
CAAAGATGG-39 and with 1/25 of the volume of the first PCR,
minimising the carry-over of the genomic DNA; control
reactions were performed with 2 and 5 ng total genomic
DNA, giving no visible amplification on gel agarose electro-
phoresis. Reaction, conditions and cycles were the same as
described previously.
9 Negative and positive controls, without a
DNA template or with a heterozygote control DNA sample
were always included. PCR products were analysed on 3%
agarose gel stained with cyber green.
Statistical analysis
Data were analysed using SPSS, version 13.0 and Prism
software (Graph-Pad, San Diego, California, USA).
Categorical and quantitative variables were respectively
described as numbers (%) and mean (SD). Sample size
calculations were based on the following assumptions: power
80%, confidence 95%, estimated difference to test between 2/2
genotype frequency of cases and controls equals 15%, ratio
between cases and controls 1:2. A minimum of 97 cases and
194 controls was derived from these calculations. A Mann–
Whitney test was used to compare continuous variables.
Categorical variables were analysed using x
2 test or Fisher test,
depending on sample size restrictions, and the odd ratios (ORs)
with 95% CI were calculated. A value of p,0.05 was
considered significant. The Hardy–Weinberg equilibrium was
calculated for all the genotyped groups.
RESULTS
Study participants’ characteristics
The study cohorts consisted of 100 patients with ERA, enrolled
before any treatment with disease-modifying antirheumatic
drugs had been initiated and 114 with LSRA. Table 1 shows the
main demographic, clinical and serological features of the
patients with RA.
Distribution of HS1,2A genotypes in patients with RA and in
controls
The genotype distribution of the HS1,2A polymorphism was
significantly different between patients with ERA and controls
(x
2
n=6=13.20, p=0.004) and the percentage of the 2/2
genotype was higher in patients with ERA (27.0%) than in
the control group (14.9%; p=0.008) (table 2). The frequency of
the allele *2 was increased in patients with ERA (53.0%) as
compared with the control group (40.0%; OR=1.73 (95% CI
1.24 to 2.40); p=0.001), whereas a lower representation of the
allele *3 (2%) in patients with ERA was seen when compared
with the controls (6%; OR=0.32 (95% CI 0.11 to 0.91);
p=0.03). The alleles *1 and 4 had comparable frequency in
patients with ERA (allele *1: 36.5% and allele *4: 8.5%) and
controls (allele *1: 43.9% and allele *4: 10.5%).
In LSRA, 34.2% of the patients carried the 2/2 genotype
(p,0.001 vs controls; table 2) and the frequency of the allele *2
was 62.7% (OR=2.58 (95% CI 1.86 to 3.56); p,0.001). A lower
representation of allele *3 and allele *4 was present in LSRA
versus controls (allele *3: 13%, OR=0.21 (95% CI 0.06 to 0.69);
p=0.03); allele *4: 1.3%, OR=0.12 (95% CI 0.04 to 0.37);
Figure 1 (A) Map of the Ig heavy chain cluster showing the duplication of four constant regions along with the two 39 regulatory regions (copy A and
copy B). The three enhancers of both 39RRs are conserved also in mice, separated by intervening sequences highly conserved for the quality of repeats
units but not for number. (B) Only the enhancer HS1,2 was found to be polymorphic. The alleles of the A and B regions are identical. On the right side of
the alleles is indicated the length of the polymorphic region of each allele. The polymorphism is based on the duplicated element of 38 bp minisatellite
(blue strips) from one to four times separated by spacers (Sp) of 20 bp (green),16 bp (violet) and 14 bp (red). The polymorphic region of allele *4 has
the substitution of the 17 bp element 59 element (El) (red spots) with a 31 bp El (orange diamonds) harbouring the consensus sequence ‘‘c’’. The letters
listed at the bottom of the figure correspond respectively to ‘‘in silicio’’ predicted transcription factors. The site ‘‘a’’ within the core not polymorphic of
the enhancer HS1,2 has the consensus for CEBP, CMYB; ‘‘b’’ presents the consensus for SP1; ‘‘c’’ has the site for AP4, E47, MYOD and mE5; ‘‘d’’
presents the consensus for IK2, MZF1 and NF-kB (P50); ‘‘e’’ has a site corresponding to NF-kB; ‘‘f’’ has the consensus for CMYB site. EMSA
experiments confirmed within alleles *1 and *2 different number of consensus for SP1 and NF-kB (unpublished data).
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agreement with those expected under the Hardy–Weinberg
equilibrium.
Genotype distribution for phenotypes of patients with RA and
relation with the autoantibody pattern
No significant association between the allele *2 of HS1,2A and
the presence of autoantibodies (anti-CCP, IgM RF, IgA RF) in
RA was seen; also, no difference was seen between patients
with ERA and those with LSRA (data not shown).
The data suggest a strict relationship between allele *2 and
RA, not with autoimmune phenotypes.
Genotype distribution in patients with ERA and relation with
clinical and laboratory variables
Carriers of HS1,2A allele *2 were 5.2 years younger than
patients without this allele (48.1 years vs 53.3 years), although
the difference did not reach significance (p=0.14). There were
no differences in gender distribution, tender and swollen joint
count and inflammatory parameters (ESR and CRP) at baseline
between HS1,2A allele *2 positive and negative patients with
ERA (data not shown).
HS1,2A polymorphism and response of patients with ERA after
12 months’ treatment
Forty-seven (48%) of 98 patients with ERA followed up for
12 months were in clinical remission (DAS44 ,1.6). Two
patients were lost at follow-up. The frequency of 2/2 genotype
was higher in the subgroup of patients not in clinical remission
(30%; OR=2.4 (95% CI 1.2 to 4.8) vs controls) than in the
cohort of patients in clinical remission (25%, OR=2.0 (95% CI
0.9 to 4.1) vs controls).
DISCUSSION
RA is characterised by polyclonal B-cell activation and produc-
tion of autoantibodies even before the appearance of arthritis,
suggesting lack of tolerance as primary event conditioning
autoreactivity.
12 These data suggest an important role for B
lymphocytes in the pathogenesis of RA as contributors of
autoimmunity, as antigen-presenting cells and T-cell stimula-
tors, and of inflammation as cytokine producers.
13
The central human enhancer HS1,2A of IgH 39RR located in
chromosome 14,q32 was polymorphic in humans and the
involvement of allele *2 in the genetic predisposition of
immune-related diseases has already been noted.
8
We found that allele *2 of the HS1,2A enhancer is
significantly more common in patients with ERA than in
healthy controls, and more common in patients with RA with
an aggressive disease not responding to treatment with
common disease-modifying antirheumatic drugs (LSRA). Allele
*2 is not associated directly with the presence of autoantibodies.
The trend suggesting that HS1,2A allele *2 might also play a role
in limiting the occurrence of disease remission in patients with
RA under adopted treatment needs confirmation in a larger
cohort with a longer follow-up.
There are no data reported with wide genome scans on the
association of chromosome 14 (region q32) with RA disease; this
may be because all studies focused mainly on the analysis of
translated and transcribed genes and not on cis-acting regula-
tory regions.
14 15 It might be interesting to develop a study for
multiple association analysis of the risk factors so far studied in
different patient populations with different techniques, includ-
ing wide genome screening if any, in order to obtain conclusive
information.
Table 1 Demographic, clinical and laboratory characteristics of
patients with early rheumatoid arthritis at baseline, and of patients with






Female, n (%) 75 (75.0) 97 (85.1)
Age (years), mean (SD) 54.9 (13.8) 57.1 (13.6)
Disease duration (years), mean (SD) 0.6 (0.3) 13.7 (10.0)
Tender joint count, mean (SD) 15.5 (10.1) 8.3 (8.9)
Swollen joint count, mean (SD) 11.4 (8.7) 5.3 (6.2)
Anti-CCP (U/ml), mean (SD) {median} 48.6 (63.4) {13.9} 49.6 (91.3) {17.0}
Anti-CCP >5 U/ml, n (%) 65 (65.0) 78 (68.4)
IgM RF (U/ml), mean (SD) {median} 61.6 (98.6) {27.1} 46.5 (78.8) {13.4}
IgM RF >20 U/ml, n (%) 54 (54.0) 47 (41.2)
IgA RF (U/ml), mean (SD) {median} 75.6 (149.9) {14.8} 52.0 (122.2) {10.2}
IgA RF >20 U/ml, n (%) 43 (43.0) 33 (28.9)
CRP (mg/l), mean (SD) 24.1 (30.6) 6.9 (11.9)
ESR (mm/1st h), mean (SD) 40.6 (24.6) 23.7 (19.5)
DAS44, mean (SD) 3.9 (1.4) 2.7 (1.4)
HAQ, mean (SD) 1.24 (0.78) 1.05 (0.80)
anti-CCP, anti-cyclic citrullinated protein; CRP, C-reactive protein; DAS, disease
activity score; ERA, early rheumatoid arthritis; ESR, erythrocyte sedimentation rate;
HAQ, Health Assessment Questionnaire; LSRA, longstanding rheumatoid arthritis; RF,
rheumatoid factor.
Table 2 Distribution of genotypes of the HS1,2A polymorphism in patients with early rheumatoid arthritis (ERA), patients with longstanding















n (%) OR (95% CI) p Value*
1/1 52 (21.0) 11 (11.0) 0.47 (0.23 to 0.94) 0.03 10 (8.8) 0.36 (0.18 to 0.74) 0.004
2/2 37 (14.9) 27 (27.0) 2.11 (1.20 to 3.70) 0.008 39 (34.2) 2.96 (1.76 to 5.00) ,0.001
3/3 2 (0.8) – 0.49 (0.02 to 10.32) 1.00 – 0.43 (0.02 to 9.05) 1.00
4/4 4 (1.6) 5 (5.0) 3.21 (0.84 to 12.22) 0.13 – 0.24 (0.01 to 4.45) 0.31
1/2 84 (33.9) 46 (46.0) 1.66 (1.04 to 267) 0.03 59 (51.8) 2.09 (1.33 to 3.29) 0.001
1/3 12 (4.8) 3 (3.0) 0.61 (0.17 to 2.20) 0.57 – 0.08 (0.00 to 1.49) 0.02
1/4 18 (7.3) 2 (2.0) 0.26 (0.06 to 1.15) 0.07 – 0.05 (0.00 to 0.91) 0.001
2/3 13 (5.2) 1 (1.0) 0.18 (0.02 to 1.42) 0.08 3 (2.6) 0.90 (0.14 to 1.75) 0.40
2/4 25 (10.1) 5 (5.0) 0.47 (0.17 to 1.26) 0.14 3 (2.6) 0.24 (0.07 to 0.82) 0.014
3/4 1 (0.4) – 0.83 (0.03 to 20.34) 1.00 – 0.72 (0.03 to 17.84) 1.00
*p Values are calculated from x
2 tests performed in patients (ERA and LSRA) versus controls.
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HS1,2A enhancer polymorphism the presence of a consensus
binding site for NF-kB, absent in allele *1.
9 Preliminary data
suggest that allele *2 of the HS1,2A polymorphism establishes a
higher affinity with NF-kB and its link with the transcription
(unpublished data). If this were the case the association with
RA could be more fully interpreted.
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